Designing a 2026 Longevity Program Patients Will Renew

The $72.3B anti-aging market rewards physicians who run programs, not procedures. Here's a 12-month program design for 2026.

Published January 18, 2026 · 9 min read · Back to Anti-Aging Doctors

$72.3B

Global anti-aging market size in 2026

Precedence Research, Anti-Aging Market 2026

29%

Year-over-year growth in physician-prescribed peptide protocols (2025 → 2026)

Alliance for Longevity Initiatives 2026 Provider Report

45M

US adults using a GLP-1 or GIP/GLP-1 agonist by end of 2026

IQVIA Institute 2026 Metabolic Therapies Outlook

83%

Longevity patients requesting biomarker-tracked programs over one-off treatments

A4M 2026 Patient Preferences Study

Why programs beat procedures

83% of longevity patients now request biomarker-tracked programs over one-off treatments (A4M 2026). A quarterly-cadence program with tracked biomarkers converts curiosity into a $10K–$40K annual relationship.

A layered 12-month program

Q1 — baseline: comprehensive labs, DEXA, VO₂max, coronary calcium, cognition. Initial peptide + hormone protocol. Q2 — biologic layer: PRP hair + facial, exosomes or MSCs for joints if indicated. Q3 — device layer: HPLT, LLLT, microneedling, ECSWT for target tissues. Q4 — reassessment: repeat biomarkers, program refresh.

The GLP-1 base layer

With 45M US adults on GLP-1s by end of 2026 (IQVIA), most longevity patients will already be on or asking about one. Own the muscle-preservation, dosing, and eventual off-ramp — that's your differentiation vs. telehealth.

Ready to add these services to your practice?

We supply biologics, devices, and peptide protocols for Anti-Aging Doctors.

Request Consultation →